Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
The patient had a high-grade DCIS with necrosis, but a 0.9 DCSionRT score
Answer from: Radiation Oncologist at Community Practice
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
Sign in or Register to read more
21306
Related Questions
Should PMRT be offered for ypN0(i+) disease if only 1-2 nodes were removed in the post-chemotherapy SLNB and there is no plan for a completion AxLND?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
In a young woman with large invasive breast carcinoma (case: pT3, lobular) s/p skin sparing mastectomy with positive anterior margin, what is the practical role for re-excision with or without PMRT?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
Do you recommend high ozonated oil for radiation dermatitis?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
Would you consider 5-fraction whole breast RT for a patient with multiple positive margins following lumpectomy for whom reexcision is not possible?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?